Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Schizophrenia

Free Subscription Articles published in Am J Psychiatry Retrieve available abstracts of 71 articles: HTML format

Single Articles

July 2024
1. JONSSON L, Horbeck E, Primerano A, Song J, et al
   Association of Occupational Dysfunction and Hospital Admissions With Different Polygenic Profiles in Bipolar Disorder.
   Am J Psychiatry. 2024;181:620-629.
   PubMed     Abstract available
   
   
   June 2024
2. KURTZ MM
   Cognitive Remediation in Schizophrenia Spectrum Illness: Evidence for Treatment Persistence.
   Am J Psychiatry. 2024;181:471-473.
   PubMed    
   
   
   
3. VANO LJ, Veronese M, McCutcheon RA, Howes OD, et al
   Neuromelanin-Sensitive MRI: A Biomarker for Treatment-Resistant Schizophrenia?
   Am J Psychiatry. 2024;181:468-470.
   PubMed    
   
   
   
4. BRENNAND KJ
   Aligning Stem Cell Models and Postmortem Studies to Query Striatal Neurodevelopment in Schizophrenia.
   Am J Psychiatry. 2024;181:465-467.
   PubMed    
   
   
   
5. BIRNBAUM R, Weinberger DR
   The Genesis of Schizophrenia: An Origin Story.
   Am J Psychiatry. 2024;181:482-492.
   PubMed     Abstract available
   
   
   
6. KALIN NH
   Advances in Understanding Schizophrenia, ADHD, and ASD.
   Am J Psychiatry. 2024;181:461-464.
   PubMed    
   
   
   
7. TRAMAZZO S, Lian W, Ajnakina O, Carlson G, et al
   Long-Term Course of Remission and Recovery in Psychotic Disorders.
   Am J Psychiatry. 2024;181:532-540.
   PubMed     Abstract available
   
   
   May 2024
8. KANG J, Castro VM, Ripperger M, Venkatesh S, et al
   Genome-Wide Association Study of Treatment-Resistant Depression: Shared Biology With Metabolic Traits.
   Am J Psychiatry. 2024 May 15:appiajp20230247. doi: 10.1176/appi.ajp.20230247.
   PubMed     Abstract available
   
   
   April 2024
9. LIGHT GA, Swerdlow NR
   Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?
   Am J Psychiatry. 2024;181:272-274.
   PubMed    
   
   
   March 2024
10. VAN DER PLUIJM M, Wengler K, Reijers PN, Cassidy CM, et al
    Neuromelanin-Sensitive MRI as Candidate Marker for Treatment Resistance in First-Episode Schizophrenia.
    Am J Psychiatry. 2024 Mar 13:appiajp20220780. doi: 10.1176/appi.ajp.20220780.
    PubMed     Abstract available
    
    
    
11. VITA A, Barlati S, Ceraso A, Nibbio G, et al
    Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Am J Psychiatry. 2024 Mar 13:appiajp20230396. doi: 10.1176/appi.ajp.20230396.
    PubMed     Abstract available
    
    
    February 2024
12. HOU Y, Xia H, He T, Zhang B, et al
    N2 Responses in Youths With Psychosis Risk Syndrome and Their Association With Clinical Outcomes: A Cohort Follow-Up Study Based on the Three-Stimulus Visual Oddball Paradigm.
    Am J Psychiatry. 2024 Feb 29:appiajp20221013. doi: 10.1176/appi.ajp.20221013.
    PubMed     Abstract available
    
    
    
13. ROGNLI EB, Hoye A, Bramness JG
    Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.
    Am J Psychiatry. 2024;181:168-169.
    PubMed    
    
    
    
14. ZHU L, Ni T, Guan F
    Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention.
    Am J Psychiatry. 2024;181:168.
    PubMed    
    
    
    November 2023
15. SAWADA T, Barbosa AR, Araujo B, McCord AE, et al
    Recapitulation of Perturbed Striatal Gene Expression Dynamics of Donor's Brains With Ventral Forebrain Organoids Derived From the Same Individuals With Schizophrenia.
    Am J Psychiatry. 2023 Nov 2:appiajp20220723. doi: 10.1176/appi.ajp.20220723.
    PubMed     Abstract available
    
    
    
16. KALIN NH
    New Insights Into Psychotic Disorders.
    Am J Psychiatry. 2023;180:779-781.
    PubMed    
    
    
    
17. VAN DER VEN E, Susser E
    Structural Racism and Risk of Schizophrenia.
    Am J Psychiatry. 2023;180:782-784.
    PubMed    
    
    
    
18. CANNON TD
    Predicting Conversion to Psychosis Using Machine Learning: Are We There Yet?
    Am J Psychiatry. 2023;180:789-791.
    PubMed    
    
    
    
19. GOFF DC, Roffman J, Holt DJ
    Another Step Toward the Prediction of Antipsychotic Treatment Response Using Functional Connectivity.
    Am J Psychiatry. 2023;180:787-788.
    PubMed    
    
    
    
20. FORSYTH JK, Bearden CE
    Rethinking the First Episode of Schizophrenia: Identifying Convergent Mechanisms During Development and Moving Toward Prediction.
    Am J Psychiatry. 2023;180:792-804.
    PubMed    
    
    
    
21. STRAWBRIDGE RJ, Graham N
    Dissecting the Genetic Relationship Between Schizophrenia and Cardiovascular Disease.
    Am J Psychiatry. 2023;180:785-786.
    PubMed    
    
    
    
22. JOSHI Y, Swerdlow N, Light G
    Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh.
    Am J Psychiatry. 2023;180:841-842.
    PubMed    
    
    
    October 2023
23. SMUCNY J, Davidson I, Carter CS
    Are We There Yet? Predicting Conversion to Psychosis Using Machine Learning.
    Am J Psychiatry. 2023 Oct 4:appiajp20220973. doi: 10.1176/appi.ajp.20220973.
    PubMed    
    
    
    September 2023
24. RODEVAND L, Rahman Z, Hindley GFL, Smeland OB, et al
    Characterizing the Shared Genetic Underpinnings of Schizophrenia and Cardiovascular Disease Risk Factors.
    Am J Psychiatry. 2023 Sep 27:appiajp20220660. doi: 10.1176/appi.ajp.20220660.
    PubMed     Abstract available
    
    
    
25. KUMAR K, Modenato C, Moreau C, Ching CRK, et al
    Subcortical Brain Alterations in Carriers of Genomic Copy Number Variants.
    Am J Psychiatry. 2023;180:685-698.
    PubMed     Abstract available
    
    
    August 2023
26. CAO H, Lencz T, Gallego JA, Rubio JM, et al
    A Functional Connectome-Based Neural Signature for Individualized Prediction of Antipsychotic Response in First-Episode Psychosis.
    Am J Psychiatry. 2023 Aug 30:appiajp20220719. doi: 10.1176/appi.ajp.20220719.
    PubMed     Abstract available
    
    
    June 2023
27. VASSOS E
    What is the Link Between Substance-Induced Psychosis and Primary Psychotic Disorders?
    Am J Psychiatry. 2023;180:404-406.
    PubMed    
    
    
    May 2023
28. ROGNLI EB, Heiberg IH, Jacobsen BK, Hoye A, et al
    Transition From Substance-Induced Psychosis to Schizophrenia Spectrum Disorder or Bipolar Disorder.
    Am J Psychiatry. 2023 May 3:appiajp22010076. doi: 10.1176/appi.ajp.22010076.
    PubMed     Abstract available
    
    
    
29. KALIN NH
    Treatment Issues Related to the Use of Psychedelics, Trichotillomania, Social Anxiety Disorder, Schizophrenia, and Opioid Use Disorder.
    Am J Psychiatry. 2023;180:321-324.
    PubMed    
    
    
    
30. VINOGRADOV S, Meyer-Kalos P
    Treating Pathologies of the Will.
    Am J Psychiatry. 2023;180:331-333.
    PubMed    
    
    
    
31. BUCHANAN RW, Kreyenbuhl J
    An Argument for Antipsychotic Polypharmacy.
    Am J Psychiatry. 2023;180:334-336.
    PubMed    
    
    
    April 2023
32. DIENEL SJ, Fish KN, Lewis DA
    The Nature of Prefrontal Cortical GABA Neuron Alterations in Schizophrenia: Markedly Lower Somatostatin and Parvalbumin Gene Expression Without Missing Neurons.
    Am J Psychiatry. 2023 Apr 19:appiajp20220676. doi: 10.1176/appi.ajp.20220676.
    PubMed     Abstract available
    
    
    
33. JOSHI YB, Molina JL, Braff DL, Green MF, et al
    Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden.
    Am J Psychiatry. 2023 Apr 11:appiajp20220649. doi: 10.1176/appi.ajp.20220649.
    PubMed    
    
    
    
34. ZWICKER A, Fullerton JM, Mullins N, Rice F, et al
    Polygenic Scores and Onset of Major Mood or Psychotic Disorders Among Offspring of Affected Parents.
    Am J Psychiatry. 2023;180:285-293.
    PubMed     Abstract available
    
    
    March 2023
35. TAIPALE H, Tanskanen A, Tiihonen J
    Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia.
    Am J Psychiatry. 2023 Mar 22:appiajp20220446. doi: 10.1176/appi.ajp.20220446.
    PubMed     Abstract available
    
    
    
36. REDDY LF, Glynn SM, McGovern JE, Sugar CA, et al
    A Novel Psychosocial Intervention for Motivational Negative Symptoms in Schizophrenia: Combined Motivational Interviewing and CBT.
    Am J Psychiatry. 2023 Mar 9:appiajp20220243. doi: 10.1176/appi.ajp.20220243.
    PubMed     Abstract available
    
    
    
37. HASSERIS S, Albinana C, Vilhjalmsson BJ, Mortensen PB, et al
    Polygenic Risk and Episode Polarity Among Individuals With Bipolar Disorder.
    Am J Psychiatry. 2023;180:200-208.
    PubMed     Abstract available
    
    
    January 2023
38. BANERJEE D, Girirajan S
    Pathogenic Variants and Ascertainment: Neuropsychiatric Disease Risk in a Health System Cohort.
    Am J Psychiatry. 2023;180:11-13.
    PubMed    
    
    
    
39. SHIMELIS H, Oetjens MT, Walsh LK, Wain KE, et al
    Prevalence and Penetrance of Rare Pathogenic Variants in Neurodevelopmental Psychiatric Genes in a Health Care System Population.
    Am J Psychiatry. 2023;180:65-72.
    PubMed     Abstract available
    
    
    December 2022
40. BARBER G, Nemeroff CB, Siegel S
    A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability.
    Am J Psychiatry. 2022;179:892-896.
    PubMed    
    
    
    November 2022
41. JONAS KG, Fochtmann LJ, Perlman G, Kane JM, et al
    Distinguishing the Effects of Lead-Time Bias and Duration of Untreated Psychosis.
    Am J Psychiatry. 2022;179:862-863.
    PubMed    
    
    
    
42. SKUSE DH
    Early-Onset Psychosis and Autism Spectrum Disorder: Similar Rates of Deleterious Copy Number Variants, Yet Diverse Phenotypic Manifestations.
    Am J Psychiatry. 2022;179:798-799.
    PubMed    
    
    
    
43. KALIN NH
    Polygenic Risk Scores and Genetics in Psychiatry.
    Am J Psychiatry. 2022;179:781-784.
    PubMed    
    
    
    
44. O'KEEFFE D, Kinsella A, Waddington JL, Clarke M, et al
    Distinguishing the Effects of Lead-Time Bias and Duration of Untreated Psychosis: Reply to Jonas et al.
    Am J Psychiatry. 2022;179:863-864.
    PubMed    
    
    
    
45. SIGSTROM R, Kowalec K, Jonsson L, Clements CC, et al
    Association Between Polygenic Risk Scores and Outcome of ECT.
    Am J Psychiatry. 2022;179:844-852.
    PubMed     Abstract available
    
    
    October 2022
46. SOLMI M, Taipale H, Holm M, Tanskanen A, et al
    Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis.
    Am J Psychiatry. 2022 Oct 6:appiajp21121189. doi: 10.1176/appi.ajp.21121189.
    PubMed     Abstract available
    
    
    September 2022
47. GREGERSEN M, Mollegaard Jepsen JR, Rohd SB, Sondergaard A, et al
    Developmental Pathways and Clinical Outcomes of Early Childhood Psychotic Experiences in Preadolescent Children at Familial High Risk of Schizophrenia or Bipolar Disorder: A Prospective, Longitudinal Cohort Study - The Danish High Risk and Resilience
    Am J Psychiatry. 2022;179:628-639.
    PubMed     Abstract available
    
    
    
48. COTTER D, Healy C, Staines L, Mongan D, et al
    Broadening the Parameters of Clinical High Risk for Psychosis.
    Am J Psychiatry. 2022;179:593-595.
    PubMed    
    
    
    August 2022
49. BROWNSTEIN CA, Douard E, Mollon J, Smith R, et al
    Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder.
    Am J Psychiatry. 2022 Aug 24:appiajp21111175. doi: 10.1176/appi.ajp.21111175.
    PubMed     Abstract available
    
    
    June 2022
50. PAUL SM, Yohn SE, Popiolek M, Miller AC, et al
    Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia.
    Am J Psychiatry. 2022 Jun 27:appiajp21101083. doi: 10.1176/appi.ajp.21101083.
    PubMed     Abstract available
    
    
    April 2022
51. CHAND GB, Singhal P, Dwyer DB, Wen J, et al
    Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population.
    Am J Psychiatry. 2022 Apr 12:appiajp21070686. doi: 10.1176/appi.ajp.21070686.
    PubMed     Abstract available
    
    
    
52. O'KEEFFE D, Kinsella A, Waddington JL, Clarke M, et al
    20-Year Prospective, Sequential Follow-Up Study of Heterogeneity in Associations of Duration of Untreated Psychosis With Symptoms, Functioning, and Quality of Life Following First-Episode Psychosis.
    Am J Psychiatry. 2022;179:288-297.
    PubMed     Abstract available
    
    
    
53. CHUNG DW, Geramita MA, Lewis DA
    Synaptic Variability and Cortical Gamma Oscillation Power in Schizophrenia.
    Am J Psychiatry. 2022;179:277-287.
    PubMed     Abstract available
    
    
    
54. KALIN NH
    Integrating Clinical and Basic Research: Opioid Use Disorder, Psychotic Illnesses, and Prefrontal Microcircuits Relevant to Schizophrenia.
    Am J Psychiatry. 2022;179:255-258.
    PubMed    
    
    
    
55. MALLA A
    Reducing Duration of Untreated Psychosis: The Neglected Dimension of Early Intervention Services.
    Am J Psychiatry. 2022;179:259-261.
    PubMed    
    
    
    
56. SOHAL VS
    Transforming Discoveries About Cortical Microcircuits and Gamma Oscillations Into New Treatments for Cognitive Deficits in Schizophrenia.
    Am J Psychiatry. 2022;179:267-276.
    PubMed     Abstract available
    
    
    March 2022
57. MANCINI V, Rochas V, Seeber M, Roehri N, et al
    Aberrant Developmental Patterns of Gamma-Band Response and Long-Range Communication Disruption in Youths With 22q11.2 Deletion Syndrome.
    Am J Psychiatry. 2022;179:204-215.
    PubMed     Abstract available
    
    
    January 2022
58. GANESH S, D'Souza DC
    Cannabis and Psychosis: Recent Epidemiological Findings Continuing the "Causality Debate".
    Am J Psychiatry. 2022;179:8-10.
    PubMed    
    
    
    
59. SANCHEZ-RICO M, Limosin F, Hoertel N
    Is a Diagnosis of Schizophrenia Spectrum Disorder Associated With Increased Mortality in Patients With COVID-19?
    Am J Psychiatry. 2022;179:71-73.
    PubMed    
    
    
    October 2021
60. KALIN NH
    Depression and Schizophrenia: Sleep, Medical Risk Factors, Biomarkers, and Treatment.
    Am J Psychiatry. 2021;178:881-884.
    PubMed    
    
    
    
61. CANNON TD
    Do the Benefits of Early Intervention Services for Psychosis Generalize and Persist in the Real World?
    Am J Psychiatry. 2021;178:890-892.
    PubMed    
    
    
    September 2021
62. KALIN NH
    Insights Into Improving Clinical Outcomes Across Psychiatric Disorders and Medical Comorbidities.
    Am J Psychiatry. 2021;178:779-782.
    PubMed    
    
    
    August 2021
63. PARKER DA, Trotti RL, McDowell JE, Keedy SK, et al
    Auditory Oddball Responses Across the Schizophrenia-Bipolar Spectrum and Their Relationship to Cognitive and Clinical Features.
    Am J Psychiatry. 2021 Aug 19:appiajp202120071043.
    PubMed     Abstract available
    
    
    July 2021
64. POSSELT CM, Albert N, Nordentoft M, Hjorthoj C, et al
    The Danish OPUS Early Intervention Services for First-Episode Psychosis: A Phase 4 Prospective Cohort Study With Comparison of Randomized Trial and Real-World Data.
    Am J Psychiatry. 2021 Jul 28:appiajp202120111596.
    PubMed     Abstract available
    
    
    
65. WEISER M, Davis JM, Brown CH, Slade EP, et al
    Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans Affairs.
    Am J Psychiatry. 2021 Jul 14:appiajp202020111657.
    PubMed     Abstract available
    
    
    
66. MARDER SR
    Changing the Face of Schizophrenia.
    Am J Psychiatry. 2021;178:584-585.
    PubMed    
    
    
    May 2021
67. JOSHI YB, Thomas ML, Braff DL, Green MF, et al
    Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia.
    Am J Psychiatry. 2021 May 14:appiajp202020081212.
    PubMed     Abstract available
    
    
    
68. ANGLIN DM, Ereshefsky S, Klaunig MJ, Bridgwater MA, et al
    From Womb to Neighborhood: A Racial Analysis of Social Determinants of Psychosis in the United States.
    Am J Psychiatry. 2021 May 3:appiajp202020071091.
    PubMed     Abstract available
    
    
    
69. HONER WG
    Better Evidence for Pharmacological Maintenance Treatment in Nonaffective Psychoses: Implications for Relapse Prevention.
    Am J Psychiatry. 2021;178:369-371.
    PubMed    
    
    
    
70. FERRARELLI F, Phillips ML
    Examining and Modulating Neural Circuits in Psychiatric Disorders With Transcranial Magnetic Stimulation and Electroencephalography: Present Practices and Future Developments.
    Am J Psychiatry. 2021;178:400-413.
    PubMed     Abstract available
    
    
    April 2021
71. AMSALEM D, Markowitz JC, Jankowski SE, Yang LH, et al
    Sustained Effect of a Brief Video in Reducing Public Stigma Toward Individuals With Psychosis: A Randomized Controlled Trial of Young Adults.
    Am J Psychiatry. 2021 Apr 26:appiajp202020091293.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.